Childhood-Onset Lupus Nephritis: Unique Aspects and Challenges in Management
This Kidney International review explains how childhood-onset lupus nephritis differs from adult disease. Children have evolving immune systems and a larger genetic contribution, and because they have rarely been included in trials, newer agents approved for adults (belimumab, obinutuzumab, voclosporin) remain seldom used in pediatric care.
Background
Childhood-onset lupus nephritis is an important glomerular disease that requires safe and effective treatment to reduce the incidence of chronic kidney disease and kidney failure. Children are not small adults with evolving immune systems, and genetics contributes substantially to its complex pathogenesis.
Key challenges
Novel treatments, notably belimumab, obinutuzumab, and voclosporin, have become available for adults over the last decade, but most children with lupus nephritis are treated with conventional immunosuppression and recommendations are extrapolated from adult data because pediatric patients have historically rarely been included in clinical trials.
Clinical implications
The review highlights several unique management issues, including the optimal definition of disease remission, prevention of relapse, the delicate balance between treatment efficacy and side effects, recognition of monogenic forms of lupus nephritis, and how treatment adherence and dedicated transition care can affect outcomes.
Category
Research
Source
Kidney International
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.